AltrixBio
Manufacturing · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
110 Canal St Ste 4, Lowell, Massachusett...Website
www.altrixbio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About AltrixBio
AltrixBio is advancing the first non-systemic, oral therapy designed to replicate the metabolic effects of bariatric surgery. Built on a well-characterized compound and supported by strong preclinical data, LuCI is a scalable platform targeting type 2 diabetes, obesity, and beyond.Explore more
AltrixBio Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is AltrixBio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
AltrixBio, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Click to see if AltrixBio had a recent Job posting/layoffs
Check out if AltrixBio is spiking on competitors!
Product Launch: Get notified when AltrixBio launches new products
Earning: See what the market has to say on AltrixBio recently announced quarterly report
Check if AltrixBio has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once AltrixBio has new funding data
Congratulate Masked Content for being promoted to Masked Content at AltrixBio
Recommended Actions
Find VP level buyers at AltrixBio
Find more new buyers
Compare Similar Companies to AltrixBio
Compare insights from companies similar to AltrixBio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
AltrixBio is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
AltrixBio is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about AltrixBio.
AltrixBio financials insights
Gather financial insights about AltrixBio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Series A
$5M
AltrixBio Tech Stack
A closer look at the technologies used by AltrixBio
See more technologies
Most Recent Scoops
Funding
Funding
New Hire
Executive Move
Executive Moves, New Hire
Executive Move
Executive Moves, Board of Directors
Executive Move
Executive Moves, Board of Directors
Executive Move
Board of Directors
AltrixBio News & Media
AltrixBio Announces Appointment of John L Brooks III to Corporate Board of Directors as Independent Member
Diabetes Expert Has Extensive Healthcare Board and Advisor Experience, Helping AltrixBio Bring Patented GI Targeting Solution to market CAMBRIDGE, Mass., Dec. 14, 2022 /PRNewswire/ -- AltrixBio, a leading early-stage biotech startup, today announced that John L Brooks III will join the...AltrixBio announces issuance of US Patent for water-activated mucoadhesive composition and formulations for LuCI™ (luminal coating of the intestine).
LOWELL, Mass., Sept. 14, 2022 /PRNewswire/ -- Altrix Bio, a leading early-stage biotech startup, announces the issuance of US Patent 11,433,094, on September 6, 2022, for the proprietary compound, LuCI™, a novel agent for the treatment of obesity-associated metabolic disorders. This is a...LuCI - Researchers present a Potentially Novel Anti-obesity Therapy for Obesity-associated Type 2 Diabetes (T2D) abstract at the International Federation for Surgery of Obesity and Metabolic Disorders (IFSO) Conference
Solution Relies on LuCI – a novel Drug Capable of Adhering to the Proximal Bowel to Replicate the Effect of Gastric Bypass Surgery for Type 2 Diabetes Patients CAMBRIDGE, Mass., Aug. 25, 2022 /PRNewswire/ -- AltrixBio, an emerging early-stage biotech startup, is presenting an abstract on...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding AltrixBio
Sign Up For FreeTo access detailed company insights
AltrixBio is advancing the first non-systemic, oral therapy designed to replicate the metabolic effects of bariatric surgery. Built on a well-characterized compound and supported by strong preclinical data, LuCI is a scalable platform targeting type 2 diabetes, obesity, and beyond.... Read More
